Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2000, p. 2932-2938, Vol. 44, No. 11
Division of Infectious Diseases, Department
of Internal Medicine,1 and Institute of
Microbiology,2 Centre Hospitalier
Universitaire Vaudois, 1011 Lausanne, Switzerland
Received 2 May 2000/Returned for modification 15 June 2000/Accepted 5 August 2000
Recent observations demonstrated that fluconazole plus cyclosporine
(Cy) synergistically killed Candida albicans in vitro. This
combination was tested in rats with C. albicans
experimental endocarditis. The MICs of fluconazole and Cy for the test
organism were 0.25 and >10 mg/liter, respectively. Rats were treated
for 5 days with either Cy, amphotericin B, fluconazole, or
fluconazole-Cy. Although used at high doses, the peak concentrations of
fluconazole in the serum of rats (up to 4.5 mg/liter) were compatible
with high-dose fluconazole therapy in humans. On the other hand, Cy concentrations in serum (up to 4.5 mg/liter) were greater than recommended therapeutic levels. Untreated rats demonstrated massive pseudohyphal growth in both the vegetations and the
kidneys. However, only the kidneys displayed concomitant
polymorphonuclear infiltration. The therapeutic results reflected this
dissociation. In the vegetations, only the fungicidal fluconazole-Cy
combination significantly decreased fungal densities compared to all
groups, including amphotericin B (P < 0.0001). In the
kidneys, all regimens except the Cy regimen were effective, but
fluconazole-Cy remained superior to amphotericin B and fluconazole
alone in sterilizing the organs (P < 0.0001). While the
mechanism responsible for the fluconazole-Cy interaction is
hypothetical, this observation opens new perspectives for fungicidal combinations between azoles and other drugs.
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Fluconazole plus Cyclosporine: a Fungicidal Combination Effective
against Experimental Endocarditis Due to Candida
albicans
*
Corresponding author. Mailing address: Division of
Infectious Diseases, Department of Internal Medicine, Centre
Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland. Phone:
41-21-314-10-26. Fax: 41-21-314-10-36. E-mail:
pmoreill{at}chuv.hospvd.ch.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |